Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 9/20 | 0.82 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2459769 | 0.90 | FDPS (1.00) | FDPSBTN3A1PDE3APKMKMT2A | |
| SCHEMBL31061112 | 0.90 | FDPS (1.00) | FDPSBTN3A1PDE3APKMKMT2A | |
| SCHEMBL8167459 | 0.84 | FDPS (0.75) | FDPSBTN3A1PDE3APKMKMT2A | |
| Hydrochloric Acid SCHEMBL9174019 | 0.82 | FDPS (0.73) | FDPSBTN3A1PDE3APKMKMT2A | |
| SCHEMBL8167482 | 0.81 | FDPS (0.71) | FDPSBTN3A1PDE3APKMKMT2A | |
| SCHEMBL8170213 | 0.78 | FDPS (0.66) | FDPSBTN3A1PDE3APKMKMT2A | |
| SCHEMBL8166214 | 0.78 | FDPS (0.66) | FDPSBTN3A1PDE3APKMKMT2A | |
| Phosphonic Acid SCHEMBL8778216 | 0.77 | FDPS (0.65) | FDPSBTN3A1PDE3APKMKMT2A | |
| SCHEMBL7863043 | 0.76 | FDPS (0.69) | FDPSBTN3A1PDE3APKMKMT2A | |
| Hydrochloric Acid SCHEMBL9169735 | 0.76 | FDPS (0.66) | FDPSBTN3A1PDE3ANAPRTTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196835-A1 | ENZYME INHIBITING COMPOUNDS AND METHODS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-08-02 | — | — | US | disclosed |
| US-20120193528-A1 | QUANTITATIVE DETERMINATION OF RISEDRONATE IN URINE BY SPE-LC-MS-MS | SANOFI-AVENTIS U.S. LLC (US) | 2012-08-02 | — | — | US | disclosed |
| US-8168437-B2 | Quantitative determination of risedronate in urine by SPE-LC-MS-MS | SANOFI-AVENTIS U.S. LLC (US) | 2012-05-01 | — | — | US | disclosed |
| US-20090320572-A1 | THE QUANTITATIVE DETERMINATION OF RISEDRONATE IN URINE BY SPE-LC-MS-MS | SANOFI-AVENTIS U.S. LLC (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196835-A1 | ENZYME INHIBITING COMPOUNDS AND METHODS | COASY, FADS2, FDPS | FDPS 3/4885BTN3A1 4124/4885PDE3A 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.